Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
[C6H10(NH2)2]PtCl2
CAS Number:
Molecular Weight:
380.17
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12161600
MDL number:
InChI
1S/C6H14N2.2ClH.Pt/c7-5-3-1-2-4-6(5)8;;;/h5-6H,1-4,7-8H2;2*1H;/q;;;+2/p-2
SMILES string
Cl[Pt]Cl.NC1CCCCC1N
InChI key
PNNCIXRVXCLADM-UHFFFAOYSA-L
reaction suitability
core: platinum, reagent type: catalyst
mp
280 °C (dec.) (lit.)
Quality Level
Related Categories
signalword
Danger
Hazard Classifications
Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
X Zhai et al.
Biochemistry, 37(46), 16307-16315 (1998-11-18)
Several eukaryotic cellular proteins recognize DNA modified by the anticancer drug cisplatin (cis-diamminedichloroplatinum(II) or cis-DDP); among these proteins is a class of DNA-binding molecules containing the HMG (high-mobility group) box DNA recognition motif. We have previously reported the extraordinarily high
Y Ohya et al.
Journal of biomaterials science. Polymer edition, 7(12), 1085-1096 (1996-01-01)
cis-Dichloro(cyclohexane-trans-l-1,2-diamine)platinum(II) (Dach-Pt(chlorato)), is a platinum complex which is expected to exhibit higher antitumor activity than, and show no cross resistance with, cisplatin. However, its strong side-effects and low water-solubility have also been cited. We report that polymer/antitumor drug conjugates shows
P F Carfagna et al.
Cancer chemotherapy and pharmacology, 27(5), 335-341 (1991-01-01)
Plasma biotransformations of tetrachloro(d,l-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) were determined in vivo at both therapeutic (3 mg/kg) and toxic (12 mg/kg) doses in Fischer 344 rats. Tetraplatin was rapidly converted to dichloro(d,l-trans)1,2-diaminocyclohexaneplatinum(II) [PtCl2(dach)]. This conversion was complete at the earliest time measured (7.5
Sachiko Kaida et al.
Cancer research, 70(18), 7031-7041 (2010-08-06)
Nanoparticle therapeutics are promising platforms for cancer therapy. However, it remains a formidable challenge to assess their distribution and clinical efficacy for therapeutic applications. Here, by using multifunctional polymeric micellar nanocarriers incorporating clinically approved gadolinium (Gd)-based magnetic resonance imaging contrast
C B Oswald et al.
Research communications in chemical pathology and pharmacology, 64(1), 41-58 (1989-04-01)
The disposition of 3H-cis-1,2-diaminocyclohexanedichloroplatinum (II) and 3H-cis-1,2-diaminocyclohexanemalonatoplatinum (II) was investigated in P388 tumor-bearing BDF1 mice. Fifteen minutes after IP administration of the drugs, the serum contained 12% of the 3H-chloride derivative and 20% of the malonate derivative. Both drugs distributed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
